Trivitron Healthcare has added two new products in the newborn screening kit for India. The objective is to create better future for newborn babies in the country by providing corrective diagnosis at birth. The two new tests are Neonatal IRT and Neonatal Toxoplasma gondii IgM that detect disorders which may harm the newborn in later stages of life.

The company is already offering a wide range of newborn screening assays through the Labsystems diagnostics brand. Among these are TSH, PKU, 17OHP, G6PD, Galactose and Toxoplasmi gondii. Together with its fully automated NS2400 platform, it has now new products to complement its newborn screening panel.

Neonatal IRT can detect disorders affecting the lungs, pancreas, intestine and liver. Whereas, Neonatal Toxoplasma gondii IgM can detect neurological and visual disabilities. With newborn screening tests, the parents can start taking precautions in the early stages of life and prevent the child from life-long disorders. Majority of infants infected in utero are asymptomatic at birth, particularly if maternal infection occurs during third trimester, with sequel appearing later in life. Congenital toxoplasmosis results in severe generalised or neurological disease in about 20 per cent to 30 per cent of the infants infected in utero; approximately 10 per cent exhibit visual involvement only and the remainder are asymptomatic at birth.

According to Dr. GSK Velu, founder and managing director, Trivitron Group of Companies, the thought behind adding two critical tests to the kit is to eradicate detected problems in the newborn at early stages for better lifestyle and to live a carefree life. The company is known for its innovation in medical technology sector and making it available and affordable to larger section of the population across the globe.

“If untreated during the early stages, problems will start appearing during their teens. Brain and nervous system damage ranges from very mild to severe, and may include seizures and intellectual disability,” he added.